Grant: Fellowship - Priority Announcement - Inflammatory Bowel Disease
University of British Columbia
$48,450.00
Assessment of the role of integrins in the modulation of phenotype, function and trafficking of human T cells in inflammatory bowel disease
FY 2015-16
Summary
Inflammatory bowel disease (IBD) is the collective term used to describe two chronically occurring diseases of the intestine, Crohn's disease (CD) and ulcerative colitis (UC). Canada has one of the highest rates of IBD in the world, and the disease burden in 2012 was estimated to be $2.8 billion. In addition, individuals who are afflicted experience a dramatic reduction in their quality of life. There is currently no cure for IBD, and many patients do not respond to treatments or eventually become refractory to them. Therefore, the development of new therapies is necessary. One such new therapeutic is known as Vedolizumab. Clinical trials have shown that it is able to improve symptoms of both CD and UC. Vedolizumab works by blocking a molecule expressed on inflammatory cells of the body. This molecule, known as a4b7 integrin is important in the migration of inflammatory cells to the intestine. Although Vedolizumab has been shown to be
effective in the treatment of IBD, the mechanism by which this occurs is not exactly understood. The purpose of this project is to assess the effect of vedolizumab on human T cells, which are a class of immune cell consisting of multiple subtypes with multiple different functions. These cells play a significant role in the pathogenesis of IBD,
thus, understanding how Vedolizumab alters their function will provide indispensable insights into the pathogenesis of and treatment options for IBD.
Department
Program
Fellowship - Priority Announcement - Inflammatory Bowel Disease
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
339990
Name
Fernando Maria R
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Partnername
Canadian Association of Gastroenterology (Oakville, Ontario); Crohn's and Colitis Canada (Toronto, Ontario)
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Fellowships - Post-PhD
Projecttitle
Assessment of the role of integrins in the modulation of phenotype, function and trafficking of human T cells in inflammatory bowel disease
Programtype2
Fellowship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$48,450
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement - Inflammatory Bowel Disease
Keyworddelim
Cd4+ T Helper Cells; Crohn'S Disease; Entyvio; Inflammatory Bowel Disease; Integrins; Regulatory T Cells; Ulcerative Colitis; Vedolizumab
Abstract
Inflammatory bowel disease (IBD) is the collective term used to describe two chronically occurring diseases of the intestine, Crohn's disease (CD) and ulcerative colitis (UC). Canada has one of the highest rates of IBD in the world, and the disease burden in 2012 was estimated to be $2.8 billion. In addition, individuals who are afflicted experience a dramatic reduction in their quality of life. There is currently no cure for IBD, and many patients do not respond to treatments or eventually become refractory to them. Therefore, the development of new therapies is necessary. One such new therapeutic is known as Vedolizumab. Clinical trials have shown that it is able to improve symptoms of both CD and UC. Vedolizumab works by blocking a molecule expressed on inflammatory cells of the body. This molecule, known as a4b7 integrin is important in the migration of inflammatory cells to the intestine. Although Vedolizumab has been shown to be
effective in the treatment of IBD, the mechanism by which this occurs is not exactly understood. The purpose of this project is to assess the effect of vedolizumab on human T cells, which are a class of immune cell consisting of multiple subtypes with multiple different functions. These cells play a significant role in the pathogenesis of IBD,
thus, understanding how Vedolizumab alters their function will provide indispensable insights into the pathogenesis of and treatment options for IBD.
Competitiondate
201511
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Fernando, Maria R
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $48,450~ $0~